Anzeige
Mehr »
Login
Montag, 23.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J7EB | ISIN: FR0011341205 | Ticker-Symbol: 5NR
Tradegate
20.12.24
16:43 Uhr
3,220 Euro
+0,022
+0,69 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOBIOTIX SA Chart 1 Jahr
5-Tage-Chart
NANOBIOTIX SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,1663,22822.12.
3,1663,22820.12.

Aktuelle News zur NANOBIOTIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiNanobiotix S.A.: NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 20241
DiNanobiotix S.A. - 6-K, Report of foreign issuer-
11.12.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
09.12.Nanobiotix S.A.: NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer155Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial23 months median Overall Survival from date...
► Artikel lesen
09.12.Nanobiotix S.A. - 6-K, Report of foreign issuer-
13.11.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company4
12.11.Nanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms180Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submissionAdded expert industry leaders to Supervisory...
► Artikel lesen
NANOBIOTIX Aktie jetzt für 0€ handeln
11.10.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company5
11.10.Nanobiotix S.A. - 6-K, Report of foreign issuer3
18.09.Nanobiotix reports 1H results2
18.09.Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results232RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune...
► Artikel lesen
18.09.Nanobiotix S.A. - 6-K, Report of foreign issuer1
04.09.Nanobiotix S.A.: NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth3
03.09.Nanobiotix S.A.: Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference2
03.09.Nanobiotix S.A. - 6-K, Report of foreign issuer1
28.08.Nanobiotix shares rated Buy by Guggenheim, focused on expanding cancer treatment applications1
09.07.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company3
09.07.Nanobiotix S.A. - 6-K, Report of foreign issuer2
02.06.Nanobiotix S.A.: Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy254Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; "ITT") who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later...
► Artikel lesen
21.05.Nanobiotix S.A.: Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth361Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3Alignment of intent to transfer the sponsorship...
► Artikel lesen
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1